Januvia 50 mg 28 tablets
Merck
Merck
Composition
Each tablet contains
Sitagliptin 50 mg
Auxiliary components
Calcium hydrogen phosphate, unmilled, Croscarmellose sodium, Magnesium stearate, Sodium stearyl fumarate
Description
Januvia (sitagliptin) is an orally active, highly selective inhibitor of the DPP-4 enzyme intended for the treatment of type 2 diabetes mellitus. By inhibiting DPP-4, sitagliptin increases the concentration of two hormones of the incretin family: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide).
Hormones of the incretin family are secreted in the intestine during the day, with their concentration increasing in response to food intake. Incretins are part of the internal physiological system of glucose homeostasis regulation. They enhance insulin secretion and suppress glucagon release in a glucose-dependent manner.
Indications
-Monotherapy
As an adjunct to diet and exercise to improve glycemic control in type 2 diabetes.
-Combination therapy
Type 2 diabetes mellitus to improve glycemic control in combination with metformin or PPAR-γ agonists (e.g., thiazolidinediones) when diet, exercise, and the listed agents alone do not lead to adequate glycemic control.
Method of Administration and Dosage
-The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor.
-The compliance of the used dosage form of a particular drug with indications for use and the dosage regimen should be strictly observed.
-Taken orally.
-Single dose: 100 mg once daily.
In case of renal failure
-Correction of the dosage regimen is required.
Contraindications
-Type 1 diabetes mellitus
-Diabetic ketoacidosis
-Pregnancy
-Lactation period (breastfeeding)
-Children and adolescents under the age of 18
-Hypersensitivity to sitagliptin or any other component of the drug
Precautions
-Renal insufficiency: Use with caution in patients with renal insufficiency. In case of moderate and severe renal failure, as well as in patients with end-stage renal failure requiring hemodialysis, a dosage adjustment is required.
-Elderly patients: Elderly patients are more likely to develop renal failure. Accordingly, as in other age groups, dose adjustment is necessary in patients with severe renal failure.
Side Effects
-From the respiratory system
Upper respiratory tract infections
Nasopharyngitis
-From the nervous system
Headache
-From the musculoskeletal system
Arthralgia
-From the digestive system
Nausea
Vomiting
Abdominal pain
Diarrhea
-Severe reactions
Acute pancreatitis, including hemorrhagic and necrotic
-Laboratory findings
An increase in uric acid in the blood
A decrease in the activity of total alkaline phosphatase and, accordingly, the bone fraction of alkaline phosphatase
Leukocytosis due to an increase in the number of neutrophils
Storage Conditions
Store at a temperature not exceeding 30°C.
Packaging
A cardboard box holds 28 tablets.